ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

McDonald’s Charity Commits $5 Million To Pediatric Research

May 17, 1991

Prostate Ultrasound Markers Concepts Approved by BSC

October 3, 1986

NIH Funding Opportunity: Outstanding Investigator Award In Cancer Research Available

July 11, 2014

CTEP’s Clinical Trials Proposals Reshaped By Discussion: BSC Next On Schedule

May 9, 1986

In Brief: Spitz elected President, ASPO: Karmanos Received $6 Million From Chrysler, Ford

May 30, 1997

FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer

September 27, 2013